Search clinical trials for: CriPec® docetaxel

Total 16101 results

Sanofi

Completed

NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)

Head and Neck Neoplasms

Tunisia, Morocco, Algeria
Spanish Lung Cancer Group

Terminated

Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma (BREC)

Non Small Cell Lung Cancer | BRCA1 Mutation

Spain
George Mason University
National Institute on Drug Abuse (NIDA)

Withdrawn

Victim Impact Modules for Jail Inmates

Substance Abuse | HIV Risk | Empathy | Guilt | Shame | Criminogenic Thinking

United States
George Mason University
National Institute on Drug Abuse (NIDA)

Unknown

Trial of Impact of Crime Group Intervention for Jail Inmates (IOC-1)

Substance Abuse | HIV Risk | Shame | Crime | Criminogenic Thinking

United States
NanOlogy, LLC
US Biotest, Inc.

Withdrawn

Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma

Kidney Cancer | Renal Cell Carcinoma | Renal Cell Cancer | Adenocarcinoma of Kidney | Adenocarcinoma, Renal
NSABP Foundation Inc
AstraZeneca

Completed

Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer

Breast Neoplasms

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

Fallopian Tube Neoplasms | Carcinoma, Ovarian Epithelial | Ovarian Cancer

United States, Germany, Israel, Canada, China, Australia, Belgium, Brazil, Chile, Colombia, Denmark, Finland, France, Ireland, Italy, Japan, Korea, Republic of, Mexico, Netherlands, New Zealand, Norway, Poland, Russian Federation, Turkey and more
Jagiellonian University

Recruiting

Prophylactic Preoperative HIPEC in Advanced Gastric Cancer at High Risk of Peritoneal Recurrence (CHIMERA)

Gastric Cancer

Poland
Samsung Medical Center

Completed

Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
First Affiliated Hospital of Guangxi Medical University

Unknown

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

Non-small Cell Lung Cancer
Incyte Corporation

Terminated

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

NSCLC (Non-small Cell Lung Carcinoma)

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Two Regimens of Docetaxel in Treating Patients Who Have Not Received Chemotherapy For Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Aichi Cancer Center

Completed

Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx

Head and Neck Cancer

Japan
National Taiwan University Hospital

Completed

Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III

NSCLC

Taiwan
Seagen Inc.

Completed

FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma

Non-Small Cell Lung Carcinoma

United States
Sanofi

Completed

Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer (Tax-Over)

Ovarian Neoplasms

Turkey
Sanofi

Completed

Induction Chemotherapy Comparing Taxotere® Cisplatin and 5-Fluorouracil (TPF) With Standard Cisplatin and 5-Fluorouracil (PF) Followed by Chemoradiation in Locally Advanced Head and Neck Cancer

Cancer

United States, France, Canada, Russian Federation, Portugal, Argentina
GlaxoSmithKline

Completed

SB-715992 In Combination With Docetaxel In Patients With Solid Tumors

Solid Tumor Cancer

United Kingdom
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer

Prostate Cancer

France
Centre Antoine Lacassagne

Completed

Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer (TAXOMET)

Prostatic Neoplasms

France
Sanofi

Completed

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

Lung Neoplasms

Spain
Modra Pharmaceuticals

Completed

ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer

Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

United States, Germany, Hungary, Poland, Russian Federation, Czechia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Non-small Cell Lung Cancer

China
Instituto Nacional de Cancer, Brazil
Sanofi

Unknown

NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After? (NeoSAMBA)

Breast Cancer

Brazil
Merck Sharp & Dohme LLC
Gynecologic Oncology Group; European Network for Gynaecological Oncological...

Active, not recruiting

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

Endometrial Neoplasms

United States, Argentina, Austria, Belgium, Canada, Chile, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Mexico, Norway, Poland, Russian Federation, Spain, Sweden, Taiwan, T... and more
Seoul National University Hospital

Completed

RIPC During Free Flap With Preoperative Radiotherapy

Ischemic Reperfusion Injury | Radiotherapy | Other Reconstructive Surgery

Korea, Republic of
Hoffmann-La Roche

Completed

A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Breast Neoplasms

Canada, United States, France, Korea, Republic of, Spain, Belgium, Germany, Russian Federation, Taiwan, Ukraine
Shanghai JMT-Bio Inc.

Not yet recruiting

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Squamous Cell Non-small Cell Lung Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Evaluation of the Safety and Efficacy of Albumin-bound Docetaxel

Advanced Solid Tumors

China
Yongchang Zhang

Recruiting

Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study (SAVE)

Non-Squamous Non Small Cell Lung Cancer

China
NCIC Clinical Trials Group

Completed

OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

Canada
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

Australia
Yong Fang
Zhejiang Cancer Hospital; Zhejiang Provincial People's Hospital; Ningbo No. 1... and other collaborators

Unknown

Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC (ACWDVDFPTAN)

Non-small Cell Lung Cancer

China
China Medical University, China
General Hospital of Shenyang Military Region; Shengjing Hospital; The People's... and other collaborators

Unknown

A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC (ALTER-L024)

Non-small Cell Lung Cancer

China
Samyang Biopharmaceuticals Corporation

Completed

Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer (DOPNP201)

Solid Tumor
National Cancer Center, Korea

Completed

A Phase I/II Study of S-1 and Weekly Docetaxel for Metastatic Gastric Carcinoma

Stomach Neoplasms

Korea, Republic of
University of Rochester

Completed

Low-Dose Taxotere® (Docetaxel) With Concurrent Radiotherapy For Localized, Inoperable Carcinoma Of The Uterine Cervix

Cervix Neoplasm

United States
National Cancer Center, Korea

Unknown

Phase II Study of Perioperative S-1 Plus Docetaxel in Patients With Localized Advanced Gastric Cancer

Stomach Neoplasms

Korea, Republic of
Westfälische Wilhelms-Universität Münster

Recruiting

Remote Ischemic Preconditioning in Septic Patients (RIPC-ICU)

Sepsis | Acute Kidney Injury | Critically Ill

Germany
Kyowa Kirin, Inc.

Recruiting

A Study of KK2269 in Adult Participants With Solid Tumors

Gastric Adenocarcinoma | Non Small Cell Lung Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

Japan
AstraZeneca

Recruiting

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) (CAPItello280)

Prostate Cancer

United States, China, Israel, Korea, Republic of, Canada, Poland, Spain, Belgium, Hungary, Japan, United Kingdom, France, Brazil, Taiwan, Australia, Turkey, Chile, Czechia, India, Mexico, Netherlands, Greece
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

Australia
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

Prostate Cancer Metastatic

China
Samsung Medical Center

Completed

Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy

Gastric Adenocarcinoma

Korea, Republic of
Montefiore Medical Center
National Cancer Institute (NCI)

Completed

Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Yale University
National Cancer Institute (NCI)

Terminated

Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Asan Medical Center
Novartis Pharmaceuticals

Completed

Dovitinib Plus Docetaxel in Gastric Cancer

Gastric Cancer

Korea, Republic of
Merck Sharp & Dohme LLC

Terminated

Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)

Advanced Solid Tumors
Pfizer

Withdrawn

A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

Breast Neoplasms

Search clinical trials for: CriPec® docetaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations